A EFICÁCIA DA EDARAVONE COMO ABORDAGEM TERAPÊUTICA NA ESCLEROSE LATERAL AMIOTRÓFICA

• DOI: https://doi.org/10.22533/at.ed.669172521085

• Palavras-chave: "ALS", "Edaravone" e "effectiveness".

• Keywords: "ALS", "Edaravone" e "effectiveness".

• Abstract: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes muscle weakness, atrophy and paralysis, with cognitive function generally preserved. Most cases are sporadic, but genetic forms also exist. Edaravone, an antioxidant, is used to slow down the progression of the disease. This study is an integrative review of the literature on the efficacy of edaravone in the treatment of ALS. A search was carried out for previous studies on the PubMed and Virtual ealth Library (VHL) platforms, using the terms “ALS”, ‘Edaravone’ and “effectiveness”. The inclusion criteria were: articles published between 2017 and 2025, controlled clinical trials and observational studies. Exclusion criteria included off-topic and duplicate articles. Through the studies analyzed, it was observed that edaravone has shown benefits in slowing down the progression of the disease, especially in the early to middle stages. It acts as an antioxidant, reducing oxidative stress in nerve cells, which is one of the factors contributing to neuronal degeneration in ALS. Although it is not a cure, studies indicate that the use of edaravone can improve motor function and prolong the time until significant loss of mobility, helping to improve patients' quality of life for some time. In conclusion, its use can be considered as part of a therapeutic approach to control the progression of ALS and provide benefits in symptom management.